
Masimo (MASI) Stock Forecast & Price Target
Masimo (MASI) Analyst Ratings
Bulls say
Masimo Corporation's financial performance shows a positive trajectory, with driver shipments exceeding expectations at 65,000 units, reflecting an 8% quarter-over-quarter and 11% year-over-year increase. The company's gross margin improved by 240 basis points year-over-year, alongside a significant rise in operating margin by 570 basis points year-over-year, indicating enhanced operational efficiency and profitability. Furthermore, management has reaffirmed its revenue guidance for 2025 while raising earnings per share guidance, suggesting optimism for continued growth driven by market share gains and new product developments in both the healthcare and non-healthcare segments.
Bears say
Masimo Corp's financial outlook is hindered by declining organic revenue in both its Healthcare and Non-Healthcare segments, leading to revised projections for 2025 and 2026 that reflect significant decreases in expected revenue. The company's growth is anticipated to slow into the mid-single digits, primarily due to lost market share in monitoring technologies and lackluster new product sales, which could adversely affect margins and earnings performance. Additional risks such as manufacturing challenges and potential impacts from GLP-1 weight loss drugs further complicate Masimo's financial position, suggesting a challenging road ahead for the company.
This aggregate rating is based on analysts' research of Masimo and is not a guaranteed prediction by Public.com or investment advice.
Masimo (MASI) Analyst Forecast & Price Prediction
Start investing in Masimo (MASI)
Order type
Buy in
Order amount
Est. shares
0 shares